The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Documenti analoghi

• The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales
  di: McCarthy, Eoghan M., et al.
  Pubblicazione: (2017)
• Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
  di: McCarthy, Eoghan M, et al.
  Pubblicazione: (2018)
• A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
  di: van Dam, Laura S, et al.
  Pubblicazione: (2020)
• British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
  di: Yee, Chee-Seng, et al.
  Pubblicazione: (2007)
• Numerical scoring for the BILAG-2004 index
  di: Yee, Chee-Seng, et al.
  Pubblicazione: (2010)